Status:

COMPLETED

Transferrin Saturation and Asthenia in Hemochromatosis

Lead Sponsor:

Rennes University Hospital

Conditions:

Hemochromatoses, Genetic

Eligibility:

All Genders

18+ years

Brief Summary

Observational study.

Detailed Description

The linked HFE genetic hemochromatosis (C282Y mutation in the homozygous state) is the most common form of genetic iron overload. Its treatment is based on bloodletting, and takes place in 2 phases, ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • homozygous C282Y ;
  • in the maintenance phase for at least 6 months ;
  • follow-up at Rennes University Hospital ;
  • patient who has not expressed his opposition to participate in the study.
  • Exclusion criteria:
  • Permanent: any cause of modification of the CST unrelated to hemochromatosis (chronic inflammatory disease, excessive consumption of alcohol ...) ;
  • Temporary: infectious syndrome within 7 days before bleeding.

Exclusion

    Key Trial Info

    Start Date :

    April 10 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    April 9 2019

    Estimated Enrollment :

    260 Patients enrolled

    Trial Details

    Trial ID

    NCT03356548

    Start Date

    April 10 2017

    End Date

    April 9 2019

    Last Update

    July 31 2019

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Rennes University Hospital

    Rennes, Britain, France, 35033

    Transferrin Saturation and Asthenia in Hemochromatosis | DecenTrialz